Extension Study of MT-1303 in Subjects With Crohn's Disease

Tanabe Pharma Corporation46 enrolled

Overview

The primary objectives of the study are: -To evaluate the long-term safety and tolerability of MT-1303 in subjects with moderate to severe active Crohn's Disease（CD）

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Crohn's Disease

Interventions

MT-1303DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The subject completed 14 week Treatment Period in the double blind MT-1303-E13 study as per Protocol. Exclusion Criteria: * Permanent discontinuation of study medication prior to the end of treatment Visit in MT-1303-E13

Locations (11)

Investigational site

City Name, Czechia

Investigational site

City Name, France

Investigational site

City Nmae, Germany

Investigational site

City Nmae, Hungary

Outcomes

Primary Outcomes

Number of Subjects with Adverse Events

Time frame: 36 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.